Actively Recruiting
Phase II Study of Monalizumab, an Anti-NKG2A Antibody, to Improve Outcomes in Adults with AML or MDS Undergoing Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide
Led by Istituto Clinico Humanitas · Updated on 2025-03-24
42
Participants Needed
2
Research Sites
91 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of Monalizumab, an anti-NKG2A monoclonal antibody, in adults with blood cancers such as Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDS who are undergoing haploidentical stem cell transplantation Haplo-SCT with post-transplant cyclophosphamide PT-Cy. This Phase II, open-label, single-arm study aims to improve outcomes by enhancing natural killer NK cell activity to reduce graft-versus-host disease GVHD and disease relapse. The trial focuses on assessing graft-versus-host disease-free and progression-free survival GPFS one year after transplantation and monitoring safety and immune function effects of Monalizumab.
CONDITIONS
Brief Title
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Research Team
D
DOMENICO MAVILIO, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
